Frequently Asked Questions
Yes. The TicVac-U® anti-tick vaccine is safe because, like most vaccines, it is a protein, made from vaccine candidate proteins for R. appendiculatus vector- the brown ear adult ticks responsible for transmitting East Coast Fever (ECF), as well as R. decoloratus which is the most common tick species that cause the tick-borne disease, Babesiosis in Uganda. Secondly, it is immunogenic in terms of antibody response meaning the vaccine works by stimulating a cow’s immune response against tick-borne antigens. Immunogenicity is a central aspect of effective vaccine development and TicVac-U fulfils this criterion. Thirdly, TicVac-U already has undergone laboratory clinical trials and is currently undergoing intense field trials and testing in order to test efficacy and safety before commercial production begins.
At the moment, we recommend every 6 months for 1 year. A booster dose (third dose) may be given at least 1 year after completion of the primary immunization series if ongoing exposure or re-exposure to tick-borne East Coast Fever is expected.
At the moment, we recommend every 6 months for 1 year. A booster third dose may be given at least 1 year after completion of the primary immunization series if ongoing exposure or re-exposure to the most common tick-borne diseases like East Coast Fever, Bovine babesiosis, or Anaplasmosis is expected.
TicVac-U® at the moment is still a vaccine candidate that's currently still undergoing field trials at specific farms in Uganda.